Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.67 |
| ▸ | MME | P08473 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 1/20 | 0.63 |
| ▸ | CPA1 | P15085 | 1/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.63 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
| ▸ | MMP8 | P22894 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 3/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030203 | 1.00 | PPARG (0.67) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL2035189 | 1.00 | PPARG (0.67) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL684726 | 0.90 | PPARG (0.62) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL13227760 | 0.90 | PPARG (0.62) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL13013217 | 0.90 | PPARG (0.62) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL23901567 | 0.89 | LTA4H (0.61) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL3499760 | 0.89 | LTA4H (0.65) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL3499757 | 0.89 | LTA4H (0.65) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL681310 | 0.88 | MMP9 (0.59) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL10272198 | 0.88 | MMP9 (0.59) | PPARGMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| CN-112321677-A | Nannocystin A analogue and preparation method and application thereof | 北京大学深圳研究生院 | 2021-02-05 | — | — | CN | disclosed |
| EP-0767800-A1 | HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0725790-A1 | SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE | PARKE DAVIS & COMPANY (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996000736-A1 | HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1996-01-11 | — | — | WO | disclosed |
| WO-1995011917-A1 | SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE | PARKE, DAVIS & COMPANY (US) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | PPARG 2794/4885MME 517/4885ACE 3626/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | PPARG 4274/4885MME 41/4885ACE 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.